Entresto’s sales exceeded KRW 40 billion last year
By | translator Kim, Jung-Ju
23.02.07 12:08:32
가나다라
0
Outpatient prescriptions recorded KRW 40.6 billion last year, a 26% rise from the previous year
Has recorded growth every quarter since its release in Q4 2017
Various attempts at its combined use with other class drugs are being actively made...including various class drugs for heart failure, etc.
▲Pic of Entresto
Sales of Novartis Korea’s chronic heart failure treatment ‘Entresto’ has exceeded KRW 40 billion 6 years into its release. According to market research institution UBIST on the 7th, Entresto’s outpatient prescription sales had recorded KRW 40.6 billion last year. This is a 26% increase from the KRW 32.3 billion it had recorded the previous year.
Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that combines the angiotensin receptor blocker (ARB) 'valsartan' and neprilysin inhibitor 'sacubitril.' The drug may be used as an alternative to an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme (ACE) inhibitor in patients with left ventric
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)